<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000795026">
  <TermName>Vizimpro</TermName>
  <TermPronunciation>(vih-ZIM-proh)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>
      A drug used to treat non-small cell lung cancer that has spread, has not already been treated, and has certain mutations (changes) in the 
      <GeneName>EGFR</GeneName>
       gene. It is also being studied in the treatment of other types of cancer. Vizimpro blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called dacomitinib and PF-00299804.
    </DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000796161" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Vizimpro&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000796160" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Vizimpro&quot;" language="es" id="_4"/>
  <SpanishTermName>Vizimpro</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>
      Medicamento que se usa para el tratamiento del cáncer de pulmón  de células no pequeñas que se diseminó, no se ha tratado y presenta ciertas mutaciones (cambios) en el gen 
      <GeneName>EGFR</GeneName>
      . También está en estudio para el tratamiento de otros tipos de cáncer. Vizimpro bloquea ciertas proteínas, lo que quizás ayude a evitar la multiplicación de células cancerosas y las destruya. Es un tipo de inhibidor de  tirosina–cinasas. También se llama dacomitinib y PF-00299804.
    </DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2018-10-02</DateFirstPublished>
  <DateLastModified>2021-10-21</DateLastModified>
  <RelatedInformation>
    <RelatedDrugSummaryRef UseWith="en" href="CDR0000795301" url="/about-cancer/treatment/drugs/dacomitinib">Dacomitinib</RelatedDrugSummaryRef>
  </RelatedInformation>
</GlossaryTerm>
